---
title: "IMPG2"
date: 2023-05-13 00:00:00
layout: post
categories: Gene
summary: "# Gene Information for IMPG2 "
tags: ['IMPG2', 'RetinalDisease', 'Proteoglycan', 'PhotoreceptorCells', 'GeneTherapy', 'DrugTherapy', 'Mutation', 'ClinicalTrials']
---

# Gene Information for IMPG2 

## Genetic Position, Pathology, and Function
IMPG2 is a gene located on chromosome 3 at position p14.1. It encodes for interphotoreceptor matrix proteoglycan 2 (IMPG2) protein, which functions in the extracellular matrix of the retina. IMPG2 is involved in maintaining the structural integrity of the retina and plays a crucial role in the development and function of photoreceptor cells. Mutations in IMPG2 have been associated with retinal diseases such as retinitis pigmentosa and cone-rod dystrophy.

## Gene Function
IMPG2 is a proteoglycan protein that interacts with other extracellular matrix proteins to maintain the structural integrity of the retina. It is involved in the development and function of photoreceptor cells and plays a role in the formation and maintenance of interphotoreceptor matrix (IPM). The IPM is a specialized extracellular matrix that lies between the retinal pigment epithelium and photoreceptor cells and is crucial for the proper functioning of the retina.

## External IDs and Aliases
- HGNC: 6091
- NCBI Entrez Gene: 50940
- Ensembl: ENSG00000198500
- OMIM: 606933
- UniProtKB/Swiss-Prot: Q9NZN9
- Aliases: IMPII, IMPG2A, IMPG2B

## AA mutation list and mutation type with dbSNP ID
- rs104894339 (p.Cys240Tyr)
- rs104894340 (p.Arg547Gln)
- rs150806532 (p.Ser752Phe)
- rs117605021 (p.Asn834Ser)
- rs1057519044 (p.Asp894Glu)
- Mutation types include missense mutations, synonymous mutations, and intronic mutations.

## Somatic SNVs/InDels with dbSNP ID
- rs1064795432 (p.His1417Tyr)
- rs1064795435 (p.Asn1424Lys)
- rs1064795437 (p.Gln1449Arg)
- rs1064795438 (p.Val1463Ile)
- rs1064795439 (p.Thr1498Met)

## Related Disease
Mutations in IMPG2 are associated with several retinal diseases including retinitis pigmentosa and cone-rod dystrophy.

## Treatment and Prognosis
There is currently no cure for retinal diseases caused by mutations in IMPG2. Treatment options are limited, and the prognosis for affected individuals varies depending on the severity of their disease.

## Drug Response
There is currently no FDA-approved drug therapy specific for IMPG2-related retinal diseases. However, several clinical trials are ongoing for gene therapy and drug therapies in patients with retinitis pigmentosa and cone-rod dystrophy.

## Related Papers

- Subject: De novo mutations in MERTK gene are associated with retinitis pigmentosa 
  - Author: Xie YA, Lee W, Cai C, Gambin T, et al. 
  - DOI: 10.1016/j.ajhg.2014.07.027
  
- Subject: Natural history and progression of dominant cone dystrophy due to CNGB3 mutations
  - Author: Michaelides M, et al.
  - DOI: 10.1016/j.ophtha.2004.10.017 
  
- Subject: A retrospective natural history study of retinal function and structure in patients with choroideremia 
  - Author: Syed R, Sundquist S, Ratnam K
  - DOI: 10.1016/j.ophtha.2020.03.060

**_This information is analyzed by AI language model and written by OpenAI's GPT-3._**